Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Crystal Lumby"'
Autor:
Poonam Puri, Disha Dumka, Nathalie Carayol, Crystal Lumby, Leonidas C. Platanias, Katja Schuster, Lance S. Terada, Simrit Parmar, Amit Verma, Harikrishnan Balachandran
Publikováno v:
Leukemia and Lymphoma. :1-13
Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cel
Autor:
Crystal Lumby, Amit Verma, Simrit Parmar, Jonathan E. Dowell, Sue Sivess-Franks, Shrisha Reddy, V. Singh
Publikováno v:
Blood. 110:4538-4538
Background: Dasatinib (BMS354825), a dual Src/Abl tyrosine kinase inhibitor, exhibits potent antileukemic effects in vitro and in vivo. Despite the well-established role of BMS354825 in the treatment of imatinib-resistant chronic myelogenous leukemia
Autor:
Jonathan E. Dowell, Simrit Parmar, Michael Axelson, Sue Sivess-Franks, Crystal Lumby, Shirisha Reddy
Publikováno v:
Blood. 110:4622-4622
Background: Myelodyplastic syndrome (MDS) is the disease of the elderly and increasingly common in the veteran population. Here we report a single institution experience with MDS at the Dallas VA Medical Center. Patients and Method: From a period of
Autor:
Dumka, Disha1 (AUTHOR), Puri, Poonam1 (AUTHOR), Carayol, Nathalie2,3,4 (AUTHOR), Lumby, Crystal1 (AUTHOR), Balachandran, Harikrishnan1 (AUTHOR), Schuster, Katja1 (AUTHOR), Verma, Amit K.5 (AUTHOR), Terada, Lance S.1 (AUTHOR), Platanias, Leonidas C.2,3,4 (AUTHOR), Parmar, Simrit1 (AUTHOR) simrit.parmar@gmail.com
Publikováno v:
Leukemia & Lymphoma. Dec2009, Vol. 50 Issue 12, p2017-2029. 13p. 1 Chart, 6 Graphs.